Sofinnova Ventures leads $20m Series D for biotech company Versartis

Sofinnova Ventures has led a $20m Series D round for Versartis to help the biotech company prepare for an international Phase 3 pediatric trial of VRS-317, a treatmet for patients with growth hormone deficiency.